- Home
- AIRI vs IPA Comparison
AIRI vs IPA Comparison
Compare AIRI & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- IPA
- Stock Information
- Founded
- AIRI 1979
- IPA 1983
- Country
- AIRI United States
- IPA Canada
- Employees
- AIRI N/A
- IPA N/A
- Industry
- AIRI Military/Government/Technical
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- IPA Health Care
- Exchange
- AIRI Nasdaq
- IPA Nasdaq
- Market Cap
- AIRI 14.4M
- IPA 15.3M
- IPO Year
- AIRI N/A
- IPA 2017
- Fundamental
- Price
- AIRI $4.48
- IPA $0.53
- Analyst Decision
- AIRI
- IPA Strong Buy
- Analyst Count
- AIRI 0
- IPA 2
- Target Price
- AIRI N/A
- IPA $5.00
- AVG Volume (30 Days)
- AIRI 89.1K
- IPA 422.7K
- Earning Date
- AIRI 11-14-2024
- IPA 03-13-2025
- Dividend Yield
- AIRI N/A
- IPA N/A
- EPS Growth
- AIRI N/A
- IPA N/A
- EPS
- AIRI N/A
- IPA N/A
- Revenue
- AIRI $53,657,000.00
- IPA $17,272,336.00
- Revenue This Year
- AIRI $7.29
- IPA $1.88
- Revenue Next Year
- AIRI $1.50
- IPA $9.90
- P/E Ratio
- AIRI N/A
- IPA N/A
- Revenue Growth
- AIRI 3.31
- IPA 6.36
- 52 Week Low
- AIRI $3.03
- IPA $0.33
- 52 Week High
- AIRI $9.44
- IPA $2.60
- Technical
- Relative Strength Index (RSI)
- AIRI 53.24
- IPA 58.77
- Support Level
- AIRI $4.26
- IPA $0.43
- Resistance Level
- AIRI $4.67
- IPA $0.59
- Average True Range (ATR)
- AIRI 0.28
- IPA 0.07
- MACD
- AIRI 0.05
- IPA 0.01
- Stochastic Oscillator
- AIRI 70.27
- IPA 71.48
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.